Why Omeros Stock Skyrocketed Today

For the most part, the stock market tends to be sedate in the late holiday season. That sure wasn't the case on Wednesday with Omeros (NASDAQ: OMER), which saw a nearly 76% share price leap after its leading pipeline drug earned U.S. Food and Drug Administration (FDA) approval.The FDA's nod came that morning, with the regulator approving Omeros's Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a potentially fatal complication from stem cell transplants. This is the first and only FDA-approved TA-TMA treatment. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool